Aardvark Therapeutics (AARD) Amortizatization of Intangibles (2024 - 2026)
Aardvark Therapeutics (AARD) posted Amortizatization of Intangibles of $118000.0 for Q1 2026, down 49.36% sequentially from $233000.0 in Q4 2025, and up 45.68% YoY from $81000.0 in Q1 2025.
Aardvark Therapeutics (AARD) Amortizatization of Intangibles (2024 - 2026) Analysis & Trends
Aardvark Therapeutics has reported Amortizatization of Intangibles for 3 years, with the latest figure at $118000.0 in Q1 2026.
- Quarterly Amortizatization of Intangibles rose 45.68% year-over-year to $118000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (up 658.76% YoY) and the FY2025 annual result came in at $1.3 million, up 1260.42% from the prior year.
- Amortizatization of Intangibles eased to $118000.0 in Q1 2026 per AARD's latest filing, from $233000.0 in the prior quarter.
- Over five years, Amortizatization of Intangibles peaked at $620000.0 in Q2 2025 and troughed at $81000.0 in Q1 2025.
- A 3-year average of $253333.3 and a median of $175500.0 in 2025 frame the typical range for Amortizatization of Intangibles.
- The sharpest annual moves came in 2025 and 2026: Amortizatization of Intangibles jumped 142.71% in 2025, then jumped 45.68% in 2026.
- Over 3 years, Amortizatization of Intangibles stood at $96000.0 in 2024, then surged by 142.71% to $233000.0 in 2025, then sank by 49.36% to $118000.0 in 2026.
- According to Business Quant data, Amortizatization of Intangibles over the past three periods registered $118000.0, $233000.0, and $372000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Aardvark Therapeutics | 147.46 Mn | 73.54 Mn | - | 19,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 19,000.00 |
| Jun 30, 2026 | 19,000.00 |
| Mar 31, 2026 | 118,000.00 |
| Mar 31, 2026 | 118,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Dec 31, 2025 | 233,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Sep 30, 2025 | 372,000.00 |
| Jun 30, 2025 | 620,000.00 |
| Jun 30, 2025 | 620,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Mar 31, 2025 | 81,000.00 |
| Dec 31, 2024 | 96,000.00 |
| Dec 31, 2024 | 96,000.00 |